Changes in Beneficial Ownership · 4
Ionetix Corp / DE /
Changes in Beneficial Ownership
Structured filing — 4
ownership.xml
Filing details
- Report period
- 2026-10-23
- Issuer
- Ionetix Corp / DE /
- Issuer CIK
- 0002108121
- Trading symbol
- NONE
Reporting owner 1
- Name
- Cameron Kevin J
- Reporting owner CIK
- 0001398422
- Relationship
- Officer
- Officer title
- President and CEO
- Address
- C/O IONETIX CORPORATION, 3130 SOVEREIGN DRIVE, LANSING, MI, 48911
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy) | 3.00 | 2026-10-23 | A · Form 4 | 1,025,600 | A | 0 | [F1] | 2036-10-23 | Common Stock | 1,025,600 | 1,025,600 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
Footnotes
- F1
- The stock option vests in 48 monthly installments, subject to a 1-year cliff, with vesting commencing on April 10, 2026.↩ 1
Signature 1
- Signed
- /s/ Phieu Phun, as Attorney-in-Fact for Cameron Kevin J
- Date
- 2026-10-27
Company context
Ionetix is a leader in cyclotron technology and radioisotope manufacturing, providing innovative solutions that enable access to scarce isotopes for diagnostic and therapeutic radiopharmaceuticals. Ionetix supplies high-purity Actinium-225 (Ac-225) and Astatine-211 (At-211) for use in targeted alpha therapies, supported by a comprehensive distribution network, contract drug manufacturing services, and specialized “white glove” logistics to ensure global access.